blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3256140

EP3256140 - COMPOSITIONS FOR EBOLA VIRUS VACCINATION [Right-click to bookmark this link]
Former [2017/51]METHODS AND COMPOSITIONS FOR EBOLA VIRUS VACCINATION
[2019/43]
StatusNo opposition filed within time limit
Status updated on  12.02.2021
Database last updated on 22.08.2024
FormerThe patent has been granted
Status updated on  28.02.2020
FormerGrant of patent is intended
Status updated on  08.01.2020
FormerRequest for examination was made
Status updated on  04.11.2019
FormerGrant of patent is intended
Status updated on  10.10.2019
FormerRequest for examination was made
Status updated on  17.11.2017
FormerThe international publication has been made
Status updated on  06.07.2017
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024  [2024/29]
Applicant(s)For all designated states
Etubics Corporation
410 West Harrison Street, Suite 200
Seattle WA 98119 / US
[2017/51]
Inventor(s)01 / JONES, Frank R.
410 West Harrison Street
Suite 200
Seattle, Washington 98119 / US
02 / GABITZSCH, Elizabeth
410 West Harrison Street
Suite 200
Seattle, Washington 98119 / US
 [2018/01]
Former [2017/51]01 / JONES, Frank R.
1124 Columbia Street
Seattle, Washington 98104 / US
02 / GABITZSCH, Elizabeth
1124 Columbia Street
Seattle, Washington 98104 / US
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2020/14]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2017/51]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date16735409.107.01.2016
[2017/51]
WO2016US12482
Priority number, dateUS201562101968P09.01.2015         Original published format: US 201562101968 P
[2017/51]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016112188
Date:14.07.2016
Language:EN
[2016/28]
Type: A1 Application with search report 
No.:EP3256140
Date:20.12.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 14.07.2016 takes the place of the publication of the European patent application.
[2017/51]
Type: B1 Patent specification 
No.:EP3256140
Date:01.04.2020
Language:EN
[2020/14]
Search report(s)International search report - published on:AU14.07.2016
(Supplementary) European search report - dispatched on:EP20.06.2018
ClassificationIPC:A61K35/761, A61K39/12, A61P31/14
[2017/51]
CPC:
A61K39/12 (EP,KR,US); A61K35/761 (US); A61K38/19 (EP,KR,US);
A61P31/14 (EP); C12N15/861 (US); A61K2300/00 (KR);
C12N2710/10043 (EP,KR,US); C12N2710/10341 (US); C12N2760/14122 (US);
C12N2760/14134 (EP,KR,US); Y02A50/30 (EP) (-)
C-Set:
A61K38/19, A61K2300/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/51]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ZUSAMMENSETZUNGEN FÜR EBOLA-VIRUS-IMPFSTOFF[2019/43]
English:COMPOSITIONS FOR EBOLA VIRUS VACCINATION[2019/43]
French:COMPOSITIONS POUR LA VACCINATION CONTRE LE VIRUS EBOLA[2019/43]
Former [2017/51]VERFAHREN UND ZUSAMMENSETZUNGEN FÜR EBOLA-VIRUS-IMPFSTOFF
Former [2017/51]METHODS AND COMPOSITIONS FOR EBOLA VIRUS VACCINATION
Former [2017/51]MÉTHODES ET COMPOSITIONS POUR LA VACCINATION CONTRE LE VIRUS EBOLA
Entry into regional phase05.07.2017National basic fee paid 
05.07.2017Search fee paid 
05.07.2017Designation fee(s) paid 
05.07.2017Examination fee paid 
Examination procedure05.07.2017Examination requested  [2017/51]
05.07.2017Date on which the examining division has become responsible
10.01.2019Amendment by applicant (claims and/or description)
11.10.2019Communication of intention to grant the patent
31.10.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
09.01.2020Communication of intention to grant the patent
19.02.2020Fee for grant paid
19.02.2020Fee for publishing/printing paid
19.02.2020Receipt of the translation of the claim(s)
Opposition(s)12.01.2021No opposition filed within time limit [2021/11]
Fees paidRenewal fee
29.01.2018Renewal fee patent year 03
22.01.2019Renewal fee patent year 04
23.01.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU07.01.2016
AL01.04.2020
AT01.04.2020
CY01.04.2020
CZ01.04.2020
DK01.04.2020
EE01.04.2020
FI01.04.2020
HR01.04.2020
LT01.04.2020
LV01.04.2020
MC01.04.2020
MK01.04.2020
NL01.04.2020
PL01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SI01.04.2020
SK01.04.2020
SM01.04.2020
TR01.04.2020
BG01.07.2020
NO01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
LU07.01.2021
[2024/29]
Former [2024/22]HU07.01.2016
AL01.04.2020
AT01.04.2020
CY01.04.2020
CZ01.04.2020
DK01.04.2020
EE01.04.2020
FI01.04.2020
HR01.04.2020
LT01.04.2020
LV01.04.2020
MC01.04.2020
MK01.04.2020
NL01.04.2020
PL01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SI01.04.2020
SK01.04.2020
SM01.04.2020
BG01.07.2020
NO01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
LU07.01.2021
Former [2023/33]HU07.01.2016
AL01.04.2020
AT01.04.2020
CY01.04.2020
CZ01.04.2020
DK01.04.2020
EE01.04.2020
FI01.04.2020
HR01.04.2020
LT01.04.2020
LV01.04.2020
MC01.04.2020
NL01.04.2020
PL01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SI01.04.2020
SK01.04.2020
SM01.04.2020
BG01.07.2020
NO01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
LU07.01.2021
Former [2023/30]AL01.04.2020
AT01.04.2020
CY01.04.2020
CZ01.04.2020
DK01.04.2020
EE01.04.2020
FI01.04.2020
HR01.04.2020
LT01.04.2020
LV01.04.2020
MC01.04.2020
NL01.04.2020
PL01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SI01.04.2020
SK01.04.2020
SM01.04.2020
BG01.07.2020
NO01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
LU07.01.2021
Former [2021/43]AL01.04.2020
AT01.04.2020
CZ01.04.2020
DK01.04.2020
EE01.04.2020
FI01.04.2020
HR01.04.2020
LT01.04.2020
LV01.04.2020
MC01.04.2020
NL01.04.2020
PL01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SI01.04.2020
SK01.04.2020
SM01.04.2020
BG01.07.2020
NO01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
LU07.01.2021
Former [2021/40]AL01.04.2020
AT01.04.2020
CZ01.04.2020
DK01.04.2020
EE01.04.2020
FI01.04.2020
HR01.04.2020
LT01.04.2020
LV01.04.2020
MC01.04.2020
NL01.04.2020
PL01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SI01.04.2020
SK01.04.2020
SM01.04.2020
BG01.07.2020
NO01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2021/24]AL01.04.2020
AT01.04.2020
CZ01.04.2020
DK01.04.2020
EE01.04.2020
FI01.04.2020
HR01.04.2020
LT01.04.2020
LV01.04.2020
NL01.04.2020
PL01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SI01.04.2020
SK01.04.2020
SM01.04.2020
BG01.07.2020
NO01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2021/10]AL01.04.2020
AT01.04.2020
CZ01.04.2020
DK01.04.2020
EE01.04.2020
FI01.04.2020
HR01.04.2020
LT01.04.2020
LV01.04.2020
NL01.04.2020
PL01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SK01.04.2020
SM01.04.2020
BG01.07.2020
NO01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2021/08]AL01.04.2020
CZ01.04.2020
DK01.04.2020
FI01.04.2020
HR01.04.2020
LT01.04.2020
LV01.04.2020
NL01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SM01.04.2020
BG01.07.2020
NO01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2021/04]AL01.04.2020
CZ01.04.2020
FI01.04.2020
HR01.04.2020
LT01.04.2020
LV01.04.2020
NL01.04.2020
RS01.04.2020
SE01.04.2020
BG01.07.2020
NO01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2020/51]CZ01.04.2020
FI01.04.2020
HR01.04.2020
LT01.04.2020
LV01.04.2020
NL01.04.2020
RS01.04.2020
SE01.04.2020
BG01.07.2020
NO01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2020/50]CZ01.04.2020
FI01.04.2020
HR01.04.2020
LT01.04.2020
LV01.04.2020
NL01.04.2020
SE01.04.2020
BG01.07.2020
NO01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2020/49]CZ01.04.2020
FI01.04.2020
LT01.04.2020
NL01.04.2020
SE01.04.2020
BG01.07.2020
NO01.07.2020
IS01.08.2020
PT17.08.2020
Former [2020/48]FI01.04.2020
LT01.04.2020
NL01.04.2020
SE01.04.2020
BG01.07.2020
NO01.07.2020
IS01.08.2020
PT17.08.2020
Former [2020/47]LT01.04.2020
BG01.07.2020
NO01.07.2020
IS01.08.2020
Former [2020/46]BG01.07.2020
IS01.08.2020
Former [2020/39]BG01.07.2020
Documents cited:Search[Y]US2013224144  (BALINT JOSEPH P [US], et al) [Y] 1-15 * page 35, line 14; examples 2-4; claim 1 *;
 [Y]WO2014031178  (ETUBICS CORP [US], et al) [Y] 1-15 * paragraph [0068]; examples 1-4 *;
 [Y]  - FRANK R JONES ET AL, "Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 29, no. 40, doi:10.1016/J.VACCINE.2011.07.073, ISSN 0264-410X, (20110710), pages 7020 - 7026, (20110727), XP028283453 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1016/j.vaccine.2011.07.073
 [Y]  - GABITZSCH E S ET AL, "A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 122, no. 1, doi:10.1016/J.IMLET.2008.11.003, ISSN 0165-2478, (20090129), pages 44 - 51, (20081213), XP025935768 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1016/j.imlet.2008.11.003
 [Y]  - LEDGERWOOD ET AL., "A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 29, no. 2, ISSN 0264-410X, (20101027), pages 304 - 313, (20101027), XP027539091 [Y] 1-15 * abstract; page 305, column right, paragraph 4 *
International search[A]WO2006033672  (UNIV PENNSYLVANIA [US], et al) [A] 1-138* See Whole Document *;
 [X]US2013224144  (BALINT JOSEPH P [US], et al) [X] 1-138 * see [0058], [0110-0112] and Examples *;
 [X]WO2014031178  (ETUBICS CORP [US], et al) [X] 1-138 * see [0084-0085], [00144] and [00146], pp. 43-45, Examples and Claims *;
 [X]  - JONES, F. et al., "Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine''.", Vaccine, (20110000), vol. 29, no. 40, doi:doi:10.1016/j.vaccine.2011.07.073, pages 7020 - 7026, XP 028283453 [X] 1-138 * see Discussion *
 [X]  - GABITZSCH, E. et al., "A Preliminary and Comparative Evaluation of a Novel Ad5 [E1-, Eb2-] Recombinant Based Vaccine Used to Induce Cell Mediated Immune Responses''.", Immunol. Lett., (20090000), vol. 122, no. 1, doi:doi:10.1016/j.imlet.2008.11.003, pages 44 - 51, XP025935768 [X] 1-138 * see Summary, Introduction and Discussion *

DOI:   http://dx.doi.org/10.1016/j.imlet.2008.11.003
 [A]  - LEDGERWOOD, J. et al., "A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults''.", Vaccine, (20110000), vol. 29, pages 304 - 313, XP 027539091 [A] 1-138 * see Whole Document *
 [A]  - HOENEN, T. et al., "Current Ebola Vaccines", Expert Opin. Biol. Ther., (20120000), vol. 12, no. 7, doi:doi:10.1517/14712598.2012.685152, pages 859 - 872, XP 002731403 [A] 1-138 * see Whole Document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.